The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies.
1/5 보강
Artificial intelligence (AI) is transforming health care by enhancing diagnostics, treatment planning, and patient monitoring.
APA
Thirugnanasambandam RP, Bauer A, D'Angelo C (2025). The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies.. Oncology (Williston Park, N.Y.), 39(10), 468-478. https://doi.org/10.46883/2025.25921057
MLA
Thirugnanasambandam RP, et al.. "The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies.." Oncology (Williston Park, N.Y.), vol. 39, no. 10, 2025, pp. 468-478.
PMID
41370240 ↗
Abstract 한글 요약
Artificial intelligence (AI) is transforming health care by enhancing diagnostics, treatment planning, and patient monitoring. In palliative oncology, particularly for hematologic malignancies, AI has shown promise in improving symptom management, prognostication, and personalized care. AI-driven models utilizing electronic health records, wearable devices, and predictive analytics aid in the early detection of symptoms, optimization of pain management, and streamlining of clinical decision-making. Machine learning algorithms have also enhanced risk stratification in leukemia, lymphoma, and multiple myeloma by integrating genomic data, imaging, and treatment responses to refine prognostic models. Additionally, AI-powered tools support cancer survivorship by monitoring late-treatment effects and aiding end-of-life care through predictive analytics for timely palliative interventions. Despite these advancements, challenges remain, including data bias, ethical concerns, and the need for prospective validation in clinical settings. Addressing these limitations will be crucial for fully integrating AI into palliative oncology and hematologic malignancy care.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.